Sandra Irbe

Recent Contributions

Reply to [ARCHIVED] Integrating M&E for Health Systems Strengthening

April 4, 2012
I would like to echo Kenny's points. From the perspective of the Global Fund as donor agency coming with its own Monitoring and Evaluation Toolkit and requiring that grant-related indicators are monitored as part of the national MandE effort, I would like to point out the following: 1) there is ...

Reply to Expert Panel Feb. 20-24: Management of Second Line anti-TB Drugs: Getting it right

Feb. 25, 2012
Dear Kaspars Thank you for outlining all the steps leading to the long delivery times of 2nd line drugs. At the Global Fund we should think how to accelerate the payment and ordering processes. Often times, the grant negotiations take long because of lack of clarity around other issues but ...

Reply to Expert Panel Feb. 20-24: Management of Second Line anti-TB Drugs: Getting it right

Feb. 22, 2012
Dear colleagues From the point of view of implementation of the Global Fund grants I would like to emphasize the need of advance planning of procurement and submission of the drug order early in advance in order to account for the long delivery time. For countries that have been importing ...


Recent Recommendations

None at this time.